Proton NMR studies of dihalogenated phenyl benzamides: two-dimensional higher quantum methodologies

The scalar coupled proton NMR spectra of many organic molecules possessing more than one phenyl ring are generally complex due to degeneracy of transitions arising from the closely resonating protons, in addition to several short- and long- range couplings experienced by each proton. Analogous situations are generally encountered in derivatives of halogenated benzanilides. Extraction of information from such spectra is challenging and demands the differentiation of spectrum pertaining to each phenyl ring and the simplification of their spectral complexity. The present study employs the blend of independent spin system filtering and the spin-state selective detection of single quantum (SO) transitions by the two-dimensional multiple quantum (MQ) methodology in achieving this goal. The precise values of the scalar couplings of very small magnitudes have been derived by double quantum resolved experiments. The experiments also provide the relative signs of heteronuclear couplings. Studies on four isomers of dilhalogenated benzanilides are reported in this work.

A QSAR study of the antiallergic activities of substituted benzamides and their structures

Multiple regression analysis (MRA) and comparative molecular field analysis (CoMFA) have been used in studies of the correlation between the antiallergic activities of substituted benzamides and their structures. The results achieved using Coh IFA based on 3D factors are much better than those obtained using MRA based on mainly 2D structural information. The CoMFA results reveal that the steric effects are more important than the electrostatic effects for the activities of substituted benzamides. (C) 1999 Elsevier Science B.V. All rights reserved.

The in vitro ejection of zinc from human immunodeficiency virus (HIV) type 1 nucleocapsid protein by disulfide benzamides with cellular anti-HIV activity.

Several disulfide benzamides have been shown to possess wide-spectrum antiretroviral activity in cell culture at low micromolar to submicromolar concentrations, inhibiting human immunodeficiency virus (HIV) type 1 (HIV-1) clinical and drug-resistant strains along with HIV-2 and simian immunodeficiency virus [Rice, W. G., Supko, J. G., Malspeis, L., Buckheit, R. W., Jr., Clanton, D., Bu, M., Graham, L., Schaeffer, C. A., Turpin, J. A., Domagala, J., Gogliotti, R., Bader, J. P., Halliday, S. M., Coren, L., Sowder, R. C., II, Arthur, L. O. & Henderson, L. E. (1995) Science 270, 1194-1197]. Rice and coworkers have proposed that the compounds act by "attacking" the two zinc fingers of HIV nucleocapsid protein. Shown here is evidence that low micromolar concentrations of the anti-HIV disulfide benzamides eject zinc from HIV nucleocapsid protein (NCp7) in vitro, as monitored by the zinc-specific fluorescent probe N-(6-methoxy-8-quinoyl)-p-toluenesulfonamide (TSQ). Structurally similar disulfide benzamides that do not inhibit HIV-1 in culture do not eject zinc, nor do analogs of the antiviral compounds with the disulfide replaced with a methylene sulfide. The kinetics of NCp7 zinc ejection by disulfide benzamides were found to be nonsaturable and biexponential, with the rate of ejection from the C-terminal zinc finger 7-fold faster than that from the N-terminal. The antiviral compounds were found to inhibit the zinc-dependent binding of NCp7 to HIV psi RNA, as studied by gel-shift assays, and the data correlated well with the zinc ejection data. Anti-HIV disulfide benzamides specifically eject NCp7 zinc and abolish the protein's ability to bind psi RNA in vitro, providing evidence for a possible antiretroviral mechanism of action of these compounds. Congeners of this class are under advanced preclinical evaluation as a potential chemotherapy for acquired immunodeficiency syndrome.

Study of H/D exchange rates to derive the strength of intramolecular hydrogen bonds in halo substituted organic building blocks: An NMR spectroscopic investigation

Rates of hydrogen/deuterium (H/D) exchange determined by H-1 NMR spectroscopy are utilized to derive the strength of hydrogen bonds and to monitor the electronic effects in the site-specific halogen substituted benzamides and anilines. The theoretical fitting of the time dependent variation of the integral areas of H-1 NMR resonances to the first order decay function permitted the determination of HID exchange rate constants (k) and their precise half-lives (t(1/2)) with high degree of reproducibility. The comparative study also permitted the unambiguous determination of relative strength of hydrogen bonds and the contribution from electronic effects on the HID exchange rate. (C) 2015 Elsevier B.V. All rights reserved.

Engineering a BCR-ABL-activated caspase for the selective elimination of leukemic cells.

Increased understanding of the precise molecular mechanisms involved in cell survival and cell death signaling pathways offers the promise of harnessing these molecules to eliminate cancer cells without damaging normal cells. Tyrosine kinase oncoproteins promote the genesis of leukemias through both increased cell proliferation and inhibition of apoptotic cell death. Although tyrosine kinase inhibitors, such as the BCR-ABL inhibitor imatinib, have demonstrated remarkable efficacy in the clinic, drug-resistant leukemias emerge in some patients because of either the acquisition of point mutations or amplification of the tyrosine kinase, resulting in a poor long-term prognosis. Here, we exploit the molecular mechanisms of caspase activation and tyrosine kinase/adaptor protein signaling to forge a unique approach for selectively killing leukemic cells through the forcible induction of apoptosis. We have engineered caspase variants that can directly be activated in response to BCR-ABL. Because we harness, rather than inhibit, the activity of leukemogenic kinases to kill transformed cells, this approach selectively eliminates leukemic cells regardless of drug-resistant mutations.

The matricellular protein CCN3 regulates NOTCH1 signalling in chronic myeloid leukaemia

Deregulated NOTCH1 has been reported in lymphoid leukaemia, although its role in chronic myeloid leukaemia (CML) is not well established. We previously reported BCR-ABL down-regulation of a novel haematopoietic regulator, CCN3, in CML; CCN3 is a non-canonical NOTCH1 ligand. This study characterizes the NOTCH1–CCN3 signalling axis in CML. In K562 cells, BCR-ABL silencing reduced full-length NOTCH1 (NOTCH1-FL) and inhibited the cleavage of NOTCH1 intracellular domain (NOTCH1-ICD), resulting in decreased expression of the NOTCH1 targets c-MYC and HES1. K562 cells stably overexpressing CCN3 (K562/CCN3) or treated with recombinant CCN3 (rCCN3) showed a significant reduction in NOTCH1 signalling (> 50% reduction in NOTCH1-ICD, p < 0.05). Gamma secretase inhibitor (GSI), which blocks NOTCH1 signalling, reduced K562/CCN3 colony formation but increased that of K562/control cells. GSI combined with either rCCN3 or imatinib reduced K562 colony formation with enhanced reduction of NOTCH1 signalling observed with combination treatments. We demonstrate an oncogenic role for NOTCH1 in CML and suggest that BCR-ABL disruption of NOTCH1–CCN3 signalling contributes to the pathogenesis of CML.

Sequential treatment with flavopiridol synergistically enhances pyrrolo-1,5-benzoxazepine-induced apoptosis in human chronic myeloid leukaemia cells including those resistant to imatinib treatment

The Bcr-Abl kinase inhibitor, imatinib mesylate, is the front line treatment for chronic myeloid leukaemia (CML), but the emergence of imatinib resistance has led to the search for alternative drug treatments and the examination of combination therapies to overcome imatinib resistance. The pro-apoptotic PBOX compounds are a recently developed novel series of microtubule targeting agents (MTAs) that depolymerise tubulin. Recent data demonstrating enhanced MTA-induced tumour cell apoptosis upon combination with the cyclin dependent kinase (CDK)-1 inhibitor flavopiridol prompted us to examine whether this compound could similarly enhance the effect of the PBOX compounds. We thus characterised the apoptotic and cell cycle events associated with combination therapy of the PBOX compounds and flavopiridol and results showed a sequence dependent, synergistic enhancement of apoptosis in CML cells including those expressing the imatinib-resistant T315I mutant. Flavopiridol reduced the number of polyploid cells formed in response to PBOX treatment but only to a small extent, suggesting that inhibition of endoreplication was unlikely to play a major role in the mechanism by which flavopiridol synergistically enhanced PBOX-induced apoptosis. The addition of flavopiridol following PBOX-6 treatment did however result in an accelerated exit from the G2/M transition accompanied by an enhanced downregulation and deactivation of the CDK1/cyclin B1 complex and an enhanced degradation of the inhibitor of apoptosis protein (IAP) survivin. In conclusion, results from this study highlight the potential of these novel series of PBOX compounds, alone or in sequential combination with flavopiridol, as an effective therapy against CML.

The novel pyrrolo-1,5-benzoxazepine, PBOX-21, potentiates the apoptotic efficacy of STI571 (imatinib mesylate) in human chronic myeloid leukaemia cells

The Bcr-Abl kinase inhibitor, STI571, is the first line treatment for chronic myeloid leukaemia (CML), but the recent emergence of STI571 resistance has led to the examination of combination therapies. In this report, we describe how a novel non-toxic G1-arresting compound, pyrrolo-1,5-benzoxazepine (PBOX)-21, potentiates the apoptotic ability of STI571 in Bcr-Abl-positive CML cells. Co-treatment of CML cells with PBOX-21 and STI571 induced more apoptosis than either drug alone in parental (K562S and LAMA84) and STI571-resistant cells lines (K562R). This potentiation of apoptosis was specific to Bcr-Abl-positive leukaemia cells with no effect observed on Bcr-Abl-negative HL-60 acute myeloid leukaemia cells. Apoptosis induced by PBOX-21/STI571 resulted in activation of caspase-8, cleavage of PARP and Bcl-2, upregulation of the pro-apoptotic protein Bim and a downregulation of Bcr-Abl. Repression of proteins involved in Bcr-Abl transformation, the anti-apoptotic proteins Mcl-1 and Bcl-(XL) was also observed. The combined lack of an early change in mitochondrial membrane potential, release of cytochrome c and cleavage of pro-caspase-9 suggests that this pathway is not involved in the initiation of apoptosis by PBOX-21/STI571. Apoptosis was significantly reduced following pre-treatment with either the general caspase inhibitor Boc-FMK or the chymotrypsin-like serine protease inhibitor TPCK, but was completely abrogated following pre-treatment with a combination of these inhibitors. This demonstrates the important role for each of these protease families in this apoptotic pathway. In conclusion, our data highlights the potential of PBOX-21 in combination with STI571 as an effective therapy against CML.

STI-571 (imatinib mesylate) enhances the apoptotic efficacy of pyrrolo-1,5-benzoxazepine-6, a novel microtubule-targeting agent, in both STI-571-sensitive and -resistant Bcr-Abl-positive human chronic myeloid leukemia cells

Interactions between the Bcr-Abl kinase inhibitor STI-571 (imatinib mesylate) and a novel microtubule-targeting agent (MTA), pyrrolo-1,5-benzoxazepine (PBOX)-6, were investigated in STI-571-sensitive and -resistant human chronic myeloid leukemia (CML) cells. Cotreatment of PBOX-6 with STI-571 induced significantly more apoptosis in Bcr-Abl-positive CML cell lines (K562 and LAMA-84) than either drug alone (P < 0.01). Cell cycle analysis of propidium iodide-stained cells showed that STI-571 significantly reduced PBOX-6-induced G2M arrest and polyploid formation with a concomitant increase in apoptosis. Similar results were obtained in K562 CML cells using lead MTAs (paclitaxel and nocodazole) in combination with STI-571. Potentiation of PBOX-6-induced apoptosis by STI-571 was specific to Bcr-Abl-positive leukemia cells with no cytoxic effects observed on normal peripheral blood cells. The combined treatment of STI-571 and PBOX-6 was associated with the down-regulation of Bcr-Abl and repression of proteins involved in Bcr-Abl transformation, namely the antiapoptotic proteins Bcl-x(L) and Mcl-1. Importantly, PBOX-6/STI-571 combinations were also effective in STI-571-resistant cells. Together, these findings highlight the potential clinical benefits in simultaneously targeting the microtubules and the Bcr-Abl oncoprotein in STI-571-sensitive and -resistant CML cells.

The CXCR2 antagonist, SCH-527123, shows antitumor activity and sensitizes cells to oxaliplatin in preclinical colon cancer models

Colorectal cancer is the second most common cause of cancer-related death in the United States. Recent studies showed that interleukin-8 (IL-8) and its receptors (CXCR1 and CXCR2) are significantly upregulated in both the tumor and its microenvironment, and act as key regulators of proliferation, angiogenesis, and metastasis. Our previous study showed that IL-8 overexpression in colorectal cancer cells triggers the upregulation of the CXCR2-mediated proliferative pathway. The aim of this study was to investigate whether the CXCR2 antagonist, SCH-527123, inhibits colorectal cancer proliferation and if it can sensitize colorectal cancer cells to oxaliplatin both in vitro and in vivo. SCH-527123 showed concentration-dependent antiproliferative effects in HCT116, Caco2, and their respective IL-8-overexpressing variants colorectal cancer cell lines. Moreover, SCH-527123 was able to suppress CXCR2-mediated signal transduction as shown through decreased phosphorylation of the NF-κB/mitogen-activated protein kinase (MAPK)/AKT pathway. These findings corresponded with decreased cell migration and invasion, while increased apoptosis in colorectal cancer cell lines. In vivo results verified that SCH-527123 treatment decreased tumor growth and microvessel density when compared with vehicle-treated tumors. Importantly, these preclinical studies showed that the combination of SCH-527123 and oxaliplatin resulted in a greater decrease in cell proliferation, tumor growth, apoptosis, and angiogenesis that was superior to single-agent treatment. Taken together, these findings suggest that targeting CXCR2 may block tumor proliferation, migration, invasion, and angiogenesis. In addition, CXCR2 blockade may further sensitize colorectal cancer to oxaliplatin treatment.

Estudos de síntese e transformação de cromonas e 4-quinolonas

Esta dissertação está dividida em duas partes. Na primeira parte reportam-se métodos de síntese de (E)-3-estirilflavonas e (E)/(Z)-2-aril- 4-cloro-3-estiril-2H-cromenos e estudos de ciclização das (E)-3- estirilflavonas em 5-arilbenzo[c]xantonas. Na segunda parte desenvolveram-se novas rotas de síntese de (E)-2-aril-3-estiril-4- quinolonas e posterior transformação em 5-fenil-12- metilbenzo[c]acridonas e 2,4-diarilfuro[3,2-c]quinolinas. Nesta parte estudou-se também a transformação de 2-aril-4-cloro-1,2-dihidroquinolina- 1,3-dicarbaldeídos em (E)/(Z)-2-aril-4-cloro-3-estiril-1,2- di-hidroquinolina-1-carbaldeídos. A síntese de novos derivados de (E)-3-estirilflavonas, abordada na primeira parte desta dissertação, envolveu estudos de otimização da reação de bromação seguida de ciclização de 3-aril-1-(2- hidroxiaril)propano-1,3-dionas/3-aril-3-hidroxi-1-(2-hidroxiaril)prop-2- en-1-onas em 3-bromoflavonas e o desenvolvimento de uma nova rota de síntese de 3-metilflavonas. As 3-metilflavonas foram sujeitas a bromação e seguidamente transformadas em sais de fosfónio antes de serem utilizadas na síntese de (E)-3-estirilflavonas via reação de Wittig. As 3-bromoflavonas foram também usadas na síntese de (E)-3- estirilflavonas via reação de Heck. A síntese de novos derivados de (E)/(Z)-2-aril-4-cloro-3-estiril-2H-cromenos, via reação de Wittig, envolveu a síntese e formilação de flavanonas. A última transformação reportada na primeira parte desta dissertação é a síntese de 5-arilbenzo[c]xantonas por reação de eletrociclização seguida de oxidação de (E)-3-estirilflavonas. Na segunda parte desta dissertação são estudadas duas vias de síntese de 2-aril-1-metil-4-quinolonas. A primeira via de síntese envolve a síntese de N-(2-acetilfenil)benzamidas, sua ciclização em 4-quinolonas seguida de metilação destas. A segunda via envolve a metilação e ciclização de N-(2-acetilfenil)benzamidas obtendo-se, num só passo, as 2-aril-1-metil-4-quinolonas. Posterior iodação das 2-aril-1-metil-4- quinolonas e subsequente reação de Heck das 2-aril-3-iodo-1-metil-4- quinolonas com estirenos comerciais possibilitaram a síntese de (E)-2- aril-3-estiril-1-metil-4-quinolonas. Estudos de eletrociclização seguidos de oxidação das (E)-2-aril-3-estiril-1-metil-4-quinolonas utilizando uma lâmpada de UV de mercúrio de alta pressão possibilitou a síntese de 5- fenil-12-metilbenzo[c]acridonas, enquanto que o aquecimento em refluxo de 1,2,4-triclorobenzeno deu origem a 2,4-diarilfuro[3,2- c]quinolinas. Nesta segunda parte aborda-se também a síntese de 2-aril-4-cloro-1,2- di-hidroquinolina-1,3-dicarbaldeídos, a partir da formilação de 2-aril- 2,3-di-hidro-4-quinolonas e a sua transformação em (E)/(Z)-2-aril-4- cloro-3-estiril-1,2-di-hidroquinolina-1-carbaldeídos por reação de Wittig. Todos os compostos sintetizados foram caracterizados por espectroscopia de ressonância magnética nuclear de protão e carbono 13C, espectros bidimensionais de correlação heteronuclear (HMBC e HSQC) e, nalguns casos espectros de efeito nuclear Overhauser (NOESY). Os novos produtos foram igualmente caracterizados por espectrometria de massa e sempre que possível análise elementar ou espectrometria de massa de alta resolução.

Current standards and progress in understanding and treatment of GIST.

Gastrointestinal stromal tumours (GIST), despite being rare, pose a relevant medical problem from the viewpoint of diagnosis and management. GIST are fragile, liable to metastasize and often located in delicate structures. Surgical options, therefore, are limited. In the last decade an improved understanding of the molecular mechanisms of the disease has resulted in novel modes of treatment. The introduction of systemic tyrosine kinase inhibitor therapy with imatinib has significantly improved the outcome of the disease and prolonged the survival of GIST patients. For many patients the acute threat of a deadly cancer has been transformed into a manageable chronic condition. Drug safety, tolerability and compliance, subjects of concern in all long-term therapies, have proven to be acceptable for the tyrosine kinase inhibitor imatinib. The present paper provides a compact overview of the epidemiology, pathophysiology and morphology of GIST, with special reference to the underlying molecular biology. Relevant aspects of diagnosis, therapy and monitoring of the disease are reviewed with particular emphasis on the available clinical evidence and recent guidelines.

Intramolecular Direct Functionalization of Cyclopropanes via Silver-Mediated, Palladium Catalysis

Au cours de la dernière décennie, le domaine de la fonctionnalisation directe des liens C–H a connu un intérêt croissant, en raison de la demande de processus chimiques moins dispendieux, plus efficaces et plus écologiques. . Les cyclopropanes représentent un motif structural souvent retrouvé dans des agents biologiquement actifs importants et dans des intermédiaires de synthèse permettant l'accès à des architectures complexes. Malgré leur valeur intrinsèque, la fonctionnalisation directe des cyclopropanes n’a pas été largement explorée. Ce mémoire traitera de deux méthodologies liées, mais tout aussi différentes, impliquant la fonctionnalisation directe des liens C–H cyclopropaniques impliquant des réactions intramoléculaires catalysées par un complex de palladium et assistées par l’argent. Le premier chapitre présentera d’abord un bref survol de la littérature sur les fondements de la fonctionnalisation directe ainsi que les contributions majeures réalisées dans ce domaine. L’accent sera notamment mis sur la fonctionnalisation des centres sp3 et sera souligné par des exemples pertinents. Les découvertes clés concernant le mécanisme et les cycles catalytiques de ces processus seront discutées. Le second chapitre décrira comment les 2-bromoanilides peuvent être utilisés pour accéder à des motifs particuliers de type spiro 3,3’ oxindoles cyclopropyliques. L'optimisation et l’étendue de la réaction seront abordés, suivis par des études mécanistiques réfutant l’hypothèse de la formation d’un intermédiaire palladium-énolate. Ces études mécanistiques comprennent une étude cinétique de l'effet isotopique ainsi que des études sur épimérisation; celles-ci ont confirmé que la réaction se produit par arylation directe. Sur la base des résultats obtenus dans le deuxième chapitre, nous aborderons ensuite la fonctionnalisation directe des benzamides cyclopropyliques lesquels, après une ouverture de cycle, donneront de nouveaux produits benzo [c] azépine-1-ones (chapitre trois). Après avoir présenté une brève optimisation et l’étendue de la réaction, nous discuterons des études mécanistiques impliquées à déduire l'ordre des événements dans le cycle catalytique et à déterminer le rôle des réactifs. Celles-ci permetteront de conclure que la fonctionnalisation de l’unité cyclopropyle se produit avant l’ouverture de cycle et que l'acétate est responsable de la déprotonation-métalation concertée. Le dernier chapitre (chapitre quatre) traitera en rétrospective de ce qui a été appris à partir de deux méthodologies divergentes et connexes et de comment ces résultats peuvent être exploités pour explorer d’autres types de fonctionnalisations directes sur des cyclopropanes.

Études vers la synthèse totale du cylindrocyclophane F et Synthèse d’hétérocycles azotés fluorescents

Dans ce mémoire, deux principaux sujets seront présentés. Nos efforts se sont d’abord tournés vers la synthèse du cylindrocyclophane F, un [7,7]-paracyclophane naturel, puis vers l’élaboration d’une nouvelle classe d’hétérocycles fluorescents. Premièrement, la cyclopropanation, une des étapes clés de la synthèse du cylindrocyclophane F, ainsi qu’une nouvelle voie de synthèse passant par une réaction de cyclopropénation ont été revisitées. La possibilité d’employer une méthode de macrocyclisation, incluant une réaction de couplage de Suzuki sur deux centres sp3, a ensuite été étudiée sur un substrat modèle. Deuxièmement, la synthèse de benzo[a]imidazo[2,1,5-c,d]indolizines à partir de N-[(6-bromo-2-pyridinyl)méthyl]benzamides a été développée. Dans un premier temps, le tandem cyclodéshydratation/aromatisation effectué en présence de 2-méthoxypyridine a été optimisé afin d’obtenir la 5-bromo-3-phénylimidazo[1,5-a]pyridine. Puis, une arylation intramoléculaire en présence d’une quantité catalytique d’un complexe de palladium a permis d’obtenir l’hétérocycle fusionné désiré. Les propriétés photochimiques de cette nouvelle classe d’hétérocycles seront aussi présentées.